Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer

Dysregulated adenosine-to-inosine (A-to-I) RNA editing is implicated in various cancers. However, no available RNA editing inhibitors have so far been developed to inhibit cancer-associated RNA editing events. Here, we decipher the RNA secondary structure of antizyme inhibitor 1 (AZIN1), one of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tay, Daryl Jin Tai, Song, Yangyang, Peng, Boya, Toh, Tan Boon, Hooi, Lissa, Toh, Desiree-Faye Kaixin, Hong, HuiQi, Tang, Sze Jing, Han, Jian, Gan, Wei Liang, Chan, Tim Hon Man, Krishna, Manchugondanahalli S., Patil, Kiran M., Maraswami, Manikantha, Loh, Teck Peng, Dan, Yock Young, Zhou, Lei, Bonney, Glenn Kunnath, Chow, Pierce Kah-Hoe, Chen, Gang, Chow, Edward Kai-Hua, Le, Minh T.N., Chen, Leilei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571177/
https://www.ncbi.nlm.nih.gov/pubmed/33974998
http://dx.doi.org/10.1016/j.ymthe.2021.05.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571177/
https://www.ncbi.nlm.nih.gov/pubmed/33974998
http://dx.doi.org/10.1016/j.ymthe.2021.05.008

Ejemplares similares